TICKERNERD
Menu
NTRANTRAHealthcare · Diagnostics & Research

NTRA Stock Forecast: Natera, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$310
−0.27% on the day

The 22 Wall Street analysts covering Natera, Inc. hold a median 12-month price target of $348 — +12.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$44.7B
Ticker Nerd rank
79 / 100
Median analyst target
$348
Analysts covering
22
Total return, dividends reinvested
1W
−3.8%
1M
+13.7%
YTD
+35.3%
1Y
+95.6%
From 52W high
−3.8%
From 52W low
+95.6%
$158
$322
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NTRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Natera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Quality
92
Revisions
91
Volatility
66
Growth
61
Value
59
Accruals
59
Issuance
26
Size
6

Momentum (94): The shares have been drifting up relative to others.

Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NTRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350$400Oct 25Jan 26Apr 26Jul 26NTRAHigh $375Median $348Low $193

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says22 analysts
19 Buy3 Hold0 Sell
Low $193Median $348High $375

The green dot is the last close — the median target sits +12.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Aug 2026CitigroupMaintainsBuy$315 → $365
12 Aug 2026GuggenheimMaintainsBuy$290 → $360
12 Aug 2026Piper SandlerMaintainsOverweight$249 → $364
12 Aug 2026Stephens & Co.MaintainsOverweight$305 → $350
7 Aug 2026BTIGMaintainsBuy$290 → $320
7 Aug 2026CitigroupMaintainsBuy$300 → $315
7 Aug 2026Evercore ISI GroupMaintainsOutperform$300 → $360
7 Aug 2026JP MorganMaintainsOverweight$315 → $360
7 Aug 2026RBC CapitalMaintainsOutperform$275 → $350
7 Aug 2026TD CowenMaintainsBuy$325 → $340
7 Aug 2026Wells FargoMaintainsEqual-Weight$220 → $284
14 July 2026Canaccord GenuityMaintainsBuy$285 → $330
14 July 2026Canaccord GenuityMaintainsBuy—
9 July 2026Morgan StanleyMaintainsOverweight$250 → $310
9 July 2026Morgan StanleyMaintainsOverweight—
6 July 2026Evercore ISI GroupMaintainsOutperform$270 → $300
6 July 2026Evercore ISI GroupMaintainsOutperform—
29 June 2026GuggenheimMaintainsBuy—
26 June 2026BernsteinReiteratesOutperform—
24 June 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NTRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Natera, Inc. (NTRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−204.2×

Cheaper than 99% of US stocks

Price / sales
16.5×

Cheaper than 10% of US stocks

Price / book
24.9×

Cheaper than 4% of US stocks

EV / EBITDA
−195.3×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
37.7%

Higher than 82% of US stocks

Earnings growth (YoY)
—
Gross margin
64.5%

Higher than 78% of US stocks

Operating margin
−10.3%

Higher than 24% of US stocks

Net margin
−7.1%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−12.5%

Higher than 34% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NTRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
NTRANatera, Inc.$44.7B
79
AAgilent Technologies, Inc.$42.1B
88
IDXXIDEXX Laboratories, Inc.$44.0B
93
WATWaters Corp.$40.4B
49
IQVIQVIA Holdings, Inc.$39.0B
92
ILMNIllumina, Inc.$29.3B
96
MTDMettler-Toledo International, Inc.$29.0B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Natera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NTRA news & analysis

Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference

MarketBeat · 15 Aug 2026positive

At the Canaccord conference, Natera CFO Mike Brophy highlighted strong second-quarter momentum across the company's women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.

Why it matters — A Natera watcher would care because the company's own leadership is reporting improving financial performance across all three business segments, with record Signatera volumes and better margins.

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Business Wire · 12 Aug 2026positive

Natera announced a new collaboration supporting a Phase 1 clinical trial sponsored by Kupando Therapeutics. Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in the trial of Kupando's immunotherapy candidate KUP-101 to assess serial circulating tumor DNA (ctDNA) dynamics in advanced skin cancers.

Why it matters — This expands the use of Natera's Latitude MRD assay into a new clinical trial for advanced skin cancers, potentially broadening its application in oncology.

Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status

Forbes · 7 Aug 2026positive

Natera shares surged over 20% to an all-time high, strengthening co-founder status as a billionaire. Shares have grown 40.6% since the start of the year from around $228, after a low closing price of $182.65 in late March.

Why it matters — A NTRA watcher would care because the stock's rise to an all-time high reflects a strong year-to-date share price performance for the company.

Natera Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Natera reported second-quarter 2026 revenue of approximately $753 million, up about 38% year over year, driven by record testing volumes and higher average selling prices across its oncology, women's health, and organ health businesses.

Why it matters — The results signal continued revenue growth and strong demand across all three of Natera's core business segments, which is relevant to NTRA shareholders tracking company performance.

FAQ

Frequently asked questions about NTRA stock

What is the NTRA stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Natera, Inc. have a median 12-month price target of $348, with estimates ranging from $193 to $375. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTRA stock a buy right now?

Of the 22 analysts covering Natera, Inc., 19 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Natera, Inc. 79 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTRA?

As at 15 Aug 2026, Natera, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will NTRA stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +12.3% from the last close, and Ticker Nerd's factor model ranks Natera, Inc. 79 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTRA stock forecast for 2030?

No analyst covering Natera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $193 to $375 over the next 12 months.

How has NTRA stock performed over the past year?

Natera, Inc. returned +95.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Natera, Inc. do?

Natera Inc. is a diagnostics company specializing in advanced genetic testing services for patients, clinicians, and healthcare systems.

What is the latest news on NTRA?

The most recent item we track (MarketBeat, 15 Aug 2026): "Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference". At the Canaccord conference, Natera CFO Mike Brophy highlighted strong second-quarter momentum across the company's women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.

Company

About Natera, Inc.

Natera Inc. is a diagnostics company specializing in advanced genetic testing services for patients, clinicians, and healthcare systems. The company focuses on analyzing cell-free DNA to support clinical decision-making across several key areas of medicine. Natera’s portfolio includes non-invasive prenatal tests that screen for chromosomal abnormalities, carrier screening tests for inherited genetic conditions, and products supporting in vitro fertilization through pre-implantation genetic testing. It also offers testing for products of conception and non-invasive paternity testing, addressing needs in reproductive health and family planning. Beyond prenatal and fertility applications, Natera provides tests used in oncology and organ health, where circulating DNA analysis can inform monitoring and risk assessment. Headquartered in Austin, Texas, Natera operates primarily through a laboratory services model, working with obstetric, fertility, oncology, and specialty practices, as well as hospital systems and reference laboratories. The company plays a prominent role in the genetic diagnostics market by providing high-complexity tests designed to integrate into routine clinical workflows and support personalized care decisions.

CEO Mr. Steven Leonard Chapman · 4,424 employees · United States · https://www.natera.com